Document:

<PAGE>   1

                                                                    EXHIBIT 10.5

THIS EMPLOYMENT AGREEMENT (the "Agreement") made as of the 15th day of March,
2000, is made, by and between ADVANCED PLANT PHARMACEUTICALS, INC., with an
address at 43 West 33rd Street, New York, NY 10001 ("APPI" or the "Company") and
DR. LEONARD BIELORY, with an address at 400 Mountain Avenue, Springfield, New
Jersey 07081 ( "Bielory" or the "Scientific Director").

                               W I T N E S S E T H

       WHEREAS, APPI is a nutriceutical company engaged in the development and
distribution of all natural, plant-derived dietary supplements; and

       WHEREAS, the Company is desirous of retaining the services of Bielory in
the position of Scientific Director for purposes of providing scientific
overview and oversight all of the Company's products; and

       WHEREAS, the Company is desirous of electing Bielory to serve as its
Chairman of the Board of Directors, subject to the approval of its current
Board; and

       WHEREAS, this Agreement shall supersede all previous consulting or
employment agreements between the Company and Bielory, except that the amount of
$126,000 accrued to January 31, 2000 from previous consulting agreements with
Dr. Bielory shall not be canceled by this Agreement and shall still be owed to
Dr. Bielory by the Company. The sum of $20,000 will be paid to Dr. Bielory upon
execution of this Agreement. The balance of $106,000 will be paid to Dr. Bielory
in monthly installments of $800, to be paid on the first day of each calendar
month beginning April 1, 2000.

NOW, THEREFORE, in consideration of the mutual covenants contained herein and
further good and valuable consideration, the undersigned parties hereby agree as
follows:

1.     Employment With APPI

       APPI hereby retains the services of Bielory to serve as the Company's
       Scientific Director (duties and responsibilities to be defined hereafter)
       and Bielory hereby agrees to serve the Company in such capacity.

2.     Duties and Responsibilities

       Bielory, in his position as Scientific Director shall perform the
       following services for the Company including, but not limited to:

       2.1    Bielory will assist APPI in developing and creating a market for
              the Company's existing products such as ACA and Lo-Chol and such
              other plant based nutriceutical product or other herbal or
              therapeutic supplements as may hereinafter be developed or
              purchased by the Company during the term of this Agreement.

       2.2    Bielory will assist the Company in developing and creating a
              market for the assets purchased from Dr. Bielory by the Company
              (the "Assets") on February 28, 2000. Bielory will use his best
              efforts to introduce the Company to distributors and purchasers of
              such Assets.

       2.3    Bielory will assist the Company in assembling a credible
              scientific advisory board for the purpose of maximizing the
              Company's business mission and financial earning potential. The
              Company acknowledges and agrees that Bielory is employed and
              engaged in other medical, academic and related activities and that
              the performance of his duties hereunder

                                       1
<PAGE>   2

              will be significantly less than full time and that the rendering
              of Scientific Director's services will be periodic and upon such
              occasions and dates as Scientific Director may choose in his
              discretion to accomplish the duties outline herein.

       2.4    The Company shall provide Bielory with coverage under the
              Company's product liability insurance with minimum coverage of
              $1,000,000. The Company shall provide Bielory with proof of
              insurance coverage in form satisfactory to Bielory, and such
              coverage shall provide that the policy of insurance shall not be
              canceled without thirty (30) days, prior written notice to
              Bielory.

       2.5    The Company shall provide Bielory, with regard to his capacity as
              Chairman of the Board of Directors, with Officer's and Director's
              insurance in amounts satisfactory to him and his counsel. APPI
              shall provide Bielory with proof of Officer's and Director's
              insurance coverage in form satisfactory to him and such coverage
              shall provide that the policy of insurance shall not be canceled
              without thirty (30) days prior written notice to Bielory.

3.     Term

       The term of this Agreement shall be for two (2) years beginning on the
       date hereof, March 15, 2000 and ending on March 15, 2002.

4.     Compensation

       4.1    For the services described in Section 2 of this Agreement, the
              Company will pay to Bielory Five Hundred Dollars ($500) per month
              commencing March 15, 2000, and shall pay such amount monthly
              continuing thereafter for a period of twelve (12) months from the
              date hereof.

       4.2    If and when the Company earns net profits equal to or in excess of
              $50,000 per month, then Bielory's monthly compensation shall be
              increased to an aggregate of $1,000 per month for the then
              remaining Term of this Agreement. The amount of the Company's "net
              profits" shall be determined by the Company's then independent
              public accountants regularly retained using generally accepted
              accounting principles.

       4.3    If and when the Company earns net profits equal to or in excess of
              $100,000 per month, then Bielory's monthly compensation shall be
              increased to an aggregate of $2,500 per month for the then
              remaining Term of this Agreement.

       4.4    If and when the Company earns net profits equal to or in excess of
              $150,000 per month, then Bielory's monthly compensation shall be
              reevaluated and subsequently determined by the board of directors
              of the Company.

       4.5    The provisions regarding compensation in this Section 4(a) are in
              addition to those compensatory arrangements under the Asset
              Purchase Agreement between Dr. Bielory and the Company dated
              February 28, 2000.

       4.6    Commencing March 1, 2000, and effective each January 1 thereafter,
              for so long as this Agreement is in effect, Bielory will receive
              an option to purchase 750,000 shares of the Company's common
              stock, par value $.0007 (the "Options"). Such Options shall be
              exercisable at any time by Bielory whether or not the parties are
              in a contractual relationship with each other at the time of the
              exercise of such Options. The exercise price for the 2000 option
              shall be the listed closing bid price of the Common Stock as of
              March 15, 2000 and the exercise price of subsequent annual option
              grants shall be the listed closing price of the first market day
              of January of each year as quoted on the

                                       2
<PAGE>   3

              Over-The-Counter Bulletin Board or that exchange on which the
              Company's Common Stock is then quoted.

       4.7    Upon acceptance by the undersigned of the terms of this Agreement,
              Bielory shall be granted 225,000 restricted shares of the
              Company's Common Stock, par value $.0007. Such stock shall be
              issued pursuant to Section 4(2) of the Securities Act of 1933, as
              amended. Such stock given to Bielory shall be valued at the
              closing bid price of the Company's common stock as quoted on the
              Over-The-Counter market as of the date hereof. Bielory shall
              acknowledge in writing to the Company that such restricted shares
              are being acquired for investment purposes only and not with a
              view towards public distribution or resale. Bielory further
              acknowledges that such stock given to him shall be restricted and
              bear the following legend:

       THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"). THESE SHARES HAVE BEEN
ACQUIRED FOR INVESTMENT PURPOSES ONLY AND NOT WITH A VIEW TOWARD DISTRIBUTION OR
RESALE. THESE SHARES MAY NOT BE MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE
TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SHARES UNDER
THE ACT, OR AN OPINION OF COUNSEL FOR THE CORPORATION THAT REGISTRATION IS NOT
REQUIRED UNDER THIS ACT OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE.

              Bielory shall be given piggyback registration rights.  if the
Company, at any time, proposes to register any of its securities for sale for
its own account or for the account of any other person (other than a
registration relating to the sale of securities to employees or consultants of
the Company pursuant to a stock option, stock purchase or similar plan) the
Company shall give written notice to Bielory thirty days prior to filing such
registration statement.

       4.8    Bielory shall be compensated additional shares of restricted stock
for various publication, speaking engagements and presentations. Specifically,
Bielory shall receive not less than 25,000 shares of the Company's stock, such
number of shares and price to be determined by the Company's Board of Directors,
for each article that is written by Bielory and published in a medical journal
or publication that is academic in nature or for speaking engagement or
presentations that are for academic purposes. Additionally, Bielory shall
receive not less than 5,000 shares of the Company's stock, such number of shares
and price to be determined by the Company's Board of Directors, for each article
that is written by Bielory and published that is of a marketing nature to
promote the Company's products and/or for speaking engagements or presentations
that will help market the Company's products.

       4.9    In the event payment for the above compensation is received by
Bielory after the tenth (10th) day of the month, or after ten (10) days from
receipt of an invoice from Bielory, whichever is applicable, or any check fails
of collection, APPI agrees to pay Bielory a service charge of five percent (5%)
for each payment that is paid late. In the event any payment is made more than
thirty days after its due date, Bielory shall be entitled to eighteen percent
(18%) interest on each past due payment until the date paid.

5.     Termination

       Bielory shall be permitted to terminate this Agreement at will, upon
       giving the Company ninety (90) days prior written notice, provided,
       however, that any compensation, options or shares given to Bielory by
       that time shall be deemed to have been earned pro rata to the date of
       termination of this Agreement. The Company shall be permitted to
       terminate the Agreement upon ninety (90) days prior written notice to
       Bielory.

                                       3
<PAGE>   4

6.     Representation and Warranties by the Company

       The Company warrants and represents that

       6.1    It is a Corporation in existence and good standing under the laws
              of the State of its incorporation, Delaware.

       6.2    The Company will take such steps as are necessary, including but
              not limited to, the payment of all premiums required to maintain
              the insurance coverage for the benefit of Bielory referenced in
              Section 2(c) and (d) above.

       6.3    The Company has the authority to enter into this Agreement.

       6.4    The Company has not filed any Petition in Bankruptcy, nor has a
              Petition in Bankruptcy or insolvency been filed in connection with
              the Company as of the date of execution of this Agreement nor is
              same contemplated by the Company.

       6.5    This Agreement has been approved by the Board of Directors of the
              Company and a resolution to that effect has been cast by such
              Board and executed by the President of the Company.

       6.6    The Company has not entered into any agreements with any
              physicians or other persons of similar qualifications to provide
              services similar to those to be provided by Bielory under this
              Agreement, and will not do so for the duration of this Agreement
              except with the prior written consent of Bielory, which may be
              withheld for any reason.

       6.7    The Company will not utilize the name and/or likeness of Bielory
              without his prior written consent, which may be withheld for any
              reason in the discretion of Bielory; however, Bielory hereby
              agrees to have his name, title, age and a brief description of his
              background incorporated in reports and forms to be submitted to
              the Securities and Exchange Commission ("SEC") so that the Company
              may comply with federal securities regulations. Bielory also
              agrees to allow his name to be incorporated in press releases by
              the Company after approval of such releases by Bielory.

7.     Representation and Warranties by Bielory

       Bielory represents and warrants that:

       7.1    He is free to serve as the Company's Scientific Director and that
              such position will not in any way conflict with other medical or
              academic duties which Bielory now has or may have during the Term
              of this Agreement.

       7.2    Bielory is a practicing physician and in addition, acts as
              consultant and advisor to other firms in the medical and health
              care industries, including but not limited to, pharmaceutical
              firms, Medical services firms, UMDNJ - New Jersey Medical School,
              Starx Asthma and Allergy Centers and others health care providers.
              It is not Bielory's intention to provide services exclusively for
              APPI in the field of Allergy and Immunology (AIDS) and related
              disorders.

8.     Confidential Information

       All data and information supplied by the undersigned parties to each
       other shall be treated by each party as confidential information unless
       it falls within the exceptions enumerated below. Bielory shall not
       disclose any confidential information supplied to Bielory by APPI to any
       third party not affiliated with APPI by common ownership and then only to
       affiliates under similar conditions

                                       4
<PAGE>   5

       of confidentiality, nor shall the Company disclose any confidential
       information supplied to the Company by Bielory, unless each party obtains
       the other's prior written consent or unless such information falls within
       the following exceptions:

       8.1    Except to the extent it can be established by competent proof that
              such confidential information was known by the disclosing party
              prior to receiving confidential information from the other
              undersigned party.

       8.2    Except to the extent that such confidential information is or
              becomes publicly known through no fault or omission attributable
              to Bielory or the Company; or except to the extent that such
              confidential information is rightfully given to the disclosing
              party from proper independent sources.

       8.3    Except to the extent that confidential information is derived
              independently of any disclosure from the undersigned parties.

       8.4    Obligations of confidentiality shall continue  for a period of
              three (3) years after the termination of this Agreement.

       8.5    All documents, data, know-how, formulas and samples provided to
              Bielory by APPI and end-products of the same are and will at all
              times remain the property of APPI and shall be returned to APPI
              when no longer needed for experimental purposes or evaluation or
              upon termination of this Agreement, whichever occurs first.

9.     PUBLICATIONS:

       Bielory agrees that he will not publish or co-author any paper relating
       to his work with APPI without the prior written approval of APPI, which
       approval will not be unreasonably withheld or delayed. Bielory further
       agrees that publications of material arising from this Agreement may be
       made by APPI, but that use of Bielory's name in connection with such
       publication will require Bielory's prior written approval, which approval
       will not be unreasonably withheld or delayed.

10.    NOTICES

       Any notice, demand or communication required, permitted or desired to be
       given hereunder, shall be deemed effectively given when personally
       delivered or mailed by prepaid certified mail, return receipt requested,
       or by overnight commercial carrier, addressed as follows:

       To:    Mr. David Lieberman
              Advanced Plant Pharmaceuticals, Inc.
              43 West 33rd Street
              New York, New York

       With A Copy To:

              Seth Farbman, Esq.
              Feder Kaszovitz Isaacson Weber Skala & Bass LLP
              750 Lexington Avenue
              New York, NY 10022

       To:    Dr. Leonard Bielory
              Scientific Director
              400 Mountain Avenue

                                       5
<PAGE>   6

              Springfield, NJ 07081

       With a Copy To:

              Abraham Borenstein, Esq.
              Bloom Borenstein, P.C.
              155 Morris Avenue
              Springfield, NJ 07081
              Facsimile (973) 379-4620

       or to such other address, and to the attention of such other person(s) or
       officer(s) as either party may designate by written notice.

11.    INDEMNIFICATION

       Bielory hereby agrees to hold APPI harmless and indemnify it against any
       and all costs, claims and damages for injuries or otherwise resulting
       from the negligence of Bielory in fulfilling Bielory's obligations
       pursuant to this agreement.

12.    WAIVER OF BREACH

       The waiver of any breach of any term or condition of this Agreement shall
       not be deemed to constitute a waiver of any other term or condition of
       this Agreement.

13.    SEVERABILITY

       If any term or provision of this Agreement or the application thereof to
       any person or circumstance shall to any extent be invalid or
       unenforceable, the remainder of this Agreement or the applicability of
       such term or provision to persons or circumstances other than those as to
       which it is held invalid or unenforceable shall not be affected thereby,
       and each term and provision of this Agreement shall be valid and
       enforceable to the fullest extent permitted by law.

14.    GOVERNING LAW

       This Agreement shall be governed by and construed and enforced in,
       accordance with the laws of the State of New Jersey. All actions
       hereunder shall be brought in the state or federal courts of the State of
       New Jersey.

15.    ENTIRE AGREEMENT

       This Agreement contains the entire Agreement of the parties with respect
       to its subject matter and no waiver, modification or change of any of its
       provisions shall be valid unless in writing and signed by the parties
       against whom such claimed waiver, modification or change is sought to be
       enforced (unless otherwise provided herein) .

                                    ADVANCED PLANT PHARMACEUTICALS, INC.

Dated:March 15, 2000                         By:/s/ David Lieberman
      --------------                         -----------------------------------
                                             David Lieberman, President

                                       6
<PAGE>   7

                                             SCIENTIFIC DIRECTOR

Dated:March 15, 2000                         By:/s/ Dr. Leonard Bielory
      --------------                            --------------------------------
                                                      Dr. Leonard Bielory

                                       7<PAGE>   1

                                                                    EXHIBIT 10.6

                             DISTRIBUTION AGREEMENT

              THIS DISTRIBUTION AGREEMENT ("Agreement") is made and entered into
       this 28th day of the month of June, 1999 by and between Advanced Plant
       Pharmaceuticals, Inc. ("APPI") a Delaware corporation, having a principal
       office at, 75 Maiden Lane, New York, New York 10038, and Ambar Pharmacies
       and Health, Inc., an Israeli corporation, having its principal offices at
       30 Aba Hilel Street, Ramat-Gan, Israel, 52532 ("Ambar").

                                   WITNESSETH

       WHEREAS, APPI manufactures and produces certain pharmaceutical "Products"
(as listed in Exhibit A attached hereto and as may be amended from time to time)
and would like Ambar to distribute such Products in Israel (hereinafter referred
to as the "Territory") and Ambar is willing to become a distributor of such
Products, all on the terms hereinafter set forth;

    NOW, THEREFORE, in consideration of the above premises and the mutual
covenants and agreements herein contained, the parties hereto agree as follows:

              1. TERM. This Agreement will remain in effect from the date hereof
until December 31, 2000, unless terminated sooner as hereinafter provided.

              2. APPOINTMENT. APPI hereby appoints Ambar during the Term of this
       Agreement, and Ambar hereby accepts such appointment, as APPI's exclusive
       distributor of the Products in the Territory.

              3. SALE AND PURCHASE OF PRODUCTS.

                     a. From the date hereof through December 31, 1999 ( the
"Initial Purchase Period"), APPI will sell to Ambar, and Ambar will purchase
from APPI the following:

       not less than 2,000 units of Lo-Chol 60/1000 ("Lo-Chol 60") at a purchase
price of $5.23 per unit and 1,000 units of ACA 70/1000 ("ACA") at a purchase
price of $17.83 for an aggregate purchase price of $28,290 (the "Initial Period
Minimum Purchase Price").

                     b. The Initial Period Minimum Purchase Price is to be paid,
in U.S dollars, as follows: ten percent (10%) of the Initial Period Minimum
Purchase Price, $2,829 is to be wired to APPI's designated bank account or shall
be paid by Ambar using its business credit card within twenty (20) business days
of the signing of this Agreement. The remaining ninety percent (90%) of the
Initial Period Minimum Purchase Price is to be wired to APPI's designated bank
account at the time Ambar places an order for the Products or Ambar may, at the
time Ambar places an order for the Products, provide evidence of approval of
payment using its business credit card or a letter of credit acceptable to APPI
such that payment will be made to APPI no later than sixty (60) days from when
APPI makes the Products available to Ambar for pick-up. (For example, after
Ambar pays 10% of the Initial Period Minimum

<PAGE>   2

Purchase Price, $2,829, then a subsequent order by Ambar for $5,000 worth of
Products would only require Ambar to pay the remaining 90% percent of the
purchase price, $4,500.)

                     c. From January 1, 2000 through December 31, 2000 (the
"Second Purchase Period"), APPI will sell to Ambar, and Ambar will purchase from
APPI, Lo-Chol 60 at a purchase price of $5.23 per unit and/or ACA at a purchase
price of $17.83 per unit, which the total cost of such Products shall not be
less than an aggregate purchase price of $60,000 (the "Second Period Minimum
Purchase Price").

                     d. The Second Period Minimum Purchase Price is to be paid,
in US dollars, as follows: ten percent (10%) of the Second Period Minimum
Purchase Price, $6,000, is to be wired to APPI's designated bank account or
shall be paid by Ambar using a letter of credit acceptable to APPI or its
business credit card on January 15, 2000. The remaining ninety percent (90%) of
the Second Period Minimum Purchase Price is to be wired to APPI's designated
bank account at the time Ambar places an order for the Products or Ambar may, at
the time Ambar places an order for the Products, provide evidence of approval of
payment using its business credit card or a letter of credit acceptable to APPI
such that payment will be made to APPI no later than sixty (60) days from when
APPI makes the Products available to Ambar for pick-up.

                     e. Payments for Products ordered by Ambar, other than the
minimum purchases as outlined in subsections (b) and (d) of this Section, is to
be wired to APPI's designated bank account at the time Ambar places an order for
the Products or Ambar may, at the time Ambar places an order for the Products,
provide evidence of approval of payment using its business credit card or a
letter of credit acceptable to APPI such that payment will be made to APPI no
later than sixty (60) days from when APPI makes the Products available to Ambar
for pick-up.

                     f. APPI, at its expense, will make available the Products
ordered by Ambar, within thirty (30) days after Ambar requests such Products.
APPI will make the Products available by giving notice to Ambar, in accordance
with Section 15 of this Agreement, that such ordered units are available for
pick up by Ambar at APPI's principal office located at 75 Maiden Lane, New York,
NY 10038. After such notice is given to Ambar and such ordered Products are made
available at APPI's principal office, title to and all risk of loss of and
damage to the Products will pass to Ambar.

       4. EXCLUSIVITY; SALES BY DISTRIBUTOR.

              a. While this Agreement is in effect, APPI hereby grants to Ambar
the exclusive rights to sell the Products in the agreed Territory . While this
Agreement remains in effect, APPI will not, directly or indirectly, sell the
Products within the Territory and will not permit anyone else, either directly
or indirectly, to sell or otherwise exploit the Products within the Territory.

              b. Ambar may sell the Products in such manner and on such terms as
approved by APPI. Ambar will comply with all applicable laws, rules and
regulations in selling and in otherwise dealing with the Products.

              c. Should APPI, in its sole discretion, decide to market and sell
the Products in any or all of

                                             1

<PAGE>   3

the "Extended Territories" (defined below), APPI acknowledges that it shall
provide Ambar with a right of first refusal to act as an exclusive distributor
for the Products in those areas subject to agreed upon terms by both parties.
The Extended Territories shall include any one or all of the following areas:
Turkey, Jordan, Holland and Denmark. APPI agrees that upon a decision by its
Board of Directors to market and sell the Products in the Extended Territories,
APPI will provide Notice to Ambar (as provided in Section 15 of this Agreement)
of such decision, upon which Ambar shall have fifteen business days to exercise
its right of first refusal by notifying the Company.

              d. Neither Ambar, nor its officers, employees or agents will be
deemed to be the agents, employees, partners, co-venturers or representatives,
legal or otherwise, of APPI for any purpose whatsoever.

       5. ADVERTISING. On the last day of the Initial Purchase Period, December
31, 1999, APPI will provide a rebate to Ambar in the amount of five percent of
the gross purchase price of the products ordered by Ambar during such period, so
long as such rebate is understood by Ambar to be used solely for marketing and
advertising of the Products in the agreed upon Territory. Evidence that such
rebate was used by Ambar solely for marketing and advertising of the Products in
the agreed upon Territory shall be provided to APPI and if such evidence is not
provided, Ambar agrees to return said rebate to APPI.

       APPI acknowledges that during the Term of this Agreement Ambar may
suggest and recommend to APPI marketing and promotional strategies to help Ambar
sell the Products in the stated Territory. APPI, after review and approval of
such marketing and promotional strategies and at APPI's sole discretion, will
match, dollar for dollar in U.S. currency, those funds which Ambar is willing to
contribute towards such marketing and promotional strategies with the
understanding and acknowledgment by Ambar that APPI will not contribute in
excess of ten thousand dollars ($10,000) throughout the Term of this Agreement.
Should APPI review and approve such marketing expenses, APPI will notify Ambar
of such approval, Ambar will notify APPI regarding the dollar amount that Ambar
expects to contribute, APPI within fifteen business days will then match such
stated amount by sending a check or wire transfer to Ambar, and Ambar will then
provide to APPI evidence that such funds were expended on the agreed upon
marketing and promotional items.

       6. CONFIDENTIALITY. Ambar hereby acknowledges and agrees that as per the
Confidentiality Agreement signed between Ambar and APPI, dated April 8, 1999 (a
copy of which is annexed hereto), all Confidential Information is and shall
remain the exclusive property of APPI.

       7. RIGHT TO RENEW. The Term of this Agreement may be renewed by written
agreement of APPI and Ambar. Nothing contained herein shall be deemed to create
any express or implied obligation on the part of either party to renew or extend
this Agreement; however, the undersigned parties agree, in six months from the
date hereof, to evaluate the success of this Agreement and may negotiate, in
good faith, a potential five year extension of this Agreement with terms to be
agreed upon. Each party in its sole discretion shall have the right to
determine, for any reason whatsoever, not to renew, continue or extend this
Agreement.

       8. PATENTS AND TRADEMARKS. Ambar acknowledges and agrees that APPI is the
sole and exclusive owner of all right, title and interest in and to the products
Lo-Chol and ACA and that Ambar will not claim or assert any rights or interests
in the trademarks or patents of such names and/or Products. Nothing contained in
this Agreement shall operate as or be construed as an assignment, grant or other
transfer of

                                             2
<PAGE>   4

any kind of any of APPI's right, title, or interest in or to any of the
trademarks or patent rights of Lo-Chol and ACA.

       9. INDEMNITY. Ambar agrees to indemnify and hold harmless APPI and its
Affiliates and any director, officer, stockholder, employee or agent of any of
them from and against any and all claims, losses, liabilities, damages, costs,
and expenses (including, but not limited to, attorneys', expert witness and
accounting fees and expenses) which may be sustained and arise out of Ambar's
activities, or those of its employees or agents, including without limitation,
any misrepresentations or misleading statements in respect of the Products or
any violation by Ambar of any of the provisions of this Agreement.

       10. EXPENSES. All expenses and costs incurred by Ambar in the performance
of its obligations under this Agreement shall be the sole responsibility of
Ambar and shall not be advanced or reimbursed by APPI other than those outlined
in Section 5 of this Agreement.

       11. ASSIGNABILITY. Ambar may not assign, transfer or delegate this
Agreement or any of its rights or obligations under this Agreement without the
prior written consent of APPI, and any attempted assignment, transfer or
delegation without such consent shall be deemed null and void and of no effect.

       12. TERMINATION. This agreement may be terminated by either party in case
of a breach of any of the material terms of this agreement by giving ninety (90)
days prior written notice to the other party. If this Agreement is terminated by
Ambar, Ambar acknowledges to fulfill payment to APPI for both of the minimum
purchase requirements as outlined in Section 3 above. If Ambar fails to meet the
stated minimum purchase requirements or fails to make timely payments in
accordance with this Agreement then APPI shall treat such action as a material
default and may terminate this Agreement and/ or seek liquidated damages from
Ambar.

       13. GOVERNING LAW. The validity, interpretation and performance of this
Agreement and any dispute connected herewith shall be governed and construed in
accordance with the laws of the Sate of New York without reference to its
conflict of law principles.

       14. ENTIRE AGREEMENT. This Agreement, constitutes the entire agreement
between APPI and Ambar. This Agreement supersedes any prior or existing
contracts and arrangements by and between APPI and Ambar for the distribution of
the Products in the Territory.

       15. NOTICE. Any notice required hereunder shall be made in writing by
hand-delivery, telefax, telex, courier, registered air mail, electronic mail, or
by any other means of delivery which enables the sending party to verily receipt
thereof Such notice shall be deemed given (a) at the actual time of receipt in
the case of hand-delivery or transmission by telefax, (b) Upon receipt of tile
addressee's answer back on the sender's machine in case of transmission by
telex, and (c) three (3) business days after sending in case of notice by
courier, cable or registered air mail. Any notices shall be sent to the
following addresses:

       If to APPI:                           If to Ambar:

       Advanced Pharmaceuticals, Inc.            Ambar Pharmacies & Health, Inc.
       Attention: Sam Berkowitz                  Ambar Abraham

                                             3

<PAGE>   5

       75 Maiden Lane                            30 Aba Hilel Street
       New York, NY 10038                        Ramat-Gan, Israel 53532

Either party may change the address to which notices are to he sent to it by
giving notice of such change of address to the other party in the manner herein
provided for giving notice.

       16. COUNTERPARTS. This Agreement may he executed in any number of
separate counterparts, each of which shall be deemed to be original but which
together shall constitute one in the same instrument.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of
the day and year first above written by their respective authorized officials.

AMBAR PHARMACIES AND HEALTH, INC.            ADVANCED PLANT
                                                   PHARMACEUTICALS, INC.

 BY /s/ Ambar Abraham                         By /s/ David Lieberman
    -----------------------                      ------------------------------
Name: Ambar Abraham                          Name:  David Lieberman
    Title:                                           Title: President

                                    EXHIBIT A

                                             4

<PAGE>   6

    -Lo-Chol  60/1000

    -ACA 70/1000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}]]